Skip to search formSkip to main contentSkip to account menu
Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the Food and Drug Administration database.
TLDR
Assessment of suicides, suicide attempts, and depressive symptom reduction in studies of 7 new antidepressants using the Food and Drug Administration database may help inform discussions about the use of placebo in antidepressant clinical trials.
View on PubMed
Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports.
TLDR
Findings fail to support either an overall difference in suicide risk between antidepressant- and placebo-treated depressed subjects in controlled trials or a difference between SSRIs and either other types of antidepressants or placebo.
View on PubMed
Severity of Depression and Response to Antidepressants and Placebo: An Analysis of the Food and Drug Administration Database
TLDR
The Food and Drug Administration database of 45 phase II and III antidepressant clinical trials assessed the frequency of statistically significant differences between antidepressants and placebo was higher in the trials that included patients with more severe depression, and early discontinuation was more frequent among patients whose mean initial HAM-D scores were higher.
View on Wolters Kluwer
The Placebo Effect: An Interdisciplinary Exploration
TLDR
Centuries of clinical experience show that placebos benefit a wide range of afflictions, but the health care community has yet to embrace and harness this important part of healing.
View via Publisher
Issues for DSM-5: whither melancholia? The case for its classification as a distinct mood disorder.
TLDR
Melancholia, a syndrome with a long history and distinctly specific psychopathological features, is inadequately differentiated from major depression by the DSM-IV specifier, and it deserves recognition as a separate identifiable mood disorder.
View on PubMed
Suicide risk in patients with anxiety disorders: a meta-analysis of the FDA database.
View on PubMed
Antidepressants versus placebo in major depression: an overview
  • Arif KhanW. Brown
  • Psychology, Medicine
    World psychiatry : official journal of the World…
  • 1 October 2015
Although the early antidepressant trials which included severely ill and hospitalized patients showed substantial drug‐placebo differences, these robust differences have not held up in the trials of…
View on Wiley
Research design features and patient characteristics associated with the outcome of antidepressant clinical trials.
TLDR
The severity of depressive symptoms before patient randomization, the dosing schedule (flexible versus fixed), the number of treatment arms, and the percentage of female patients were significantly associated with the difference in response to antidepressant and placebo.
View on PubMed
The Weariness of the Self: Diagnosing the History of Depression in the Contemporary Age
View via Publisher
A Systematic Review of Comparative Efficacy of Treatments and Controls for Depression
TLDR
The combination of psychotherapy and antidepressants for depression may provide a slight advantage whereas antidepressants alone and psychotherapy alone are not significantly different from alternative therapies or active intervention controls.
View PDF
...
...
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License